Analysis of economic and social costs of adverse events associated with blood transfusions in Spain |
| |
Authors: | Borja Ribed-Sánchez Cristina González-Gaya Sara Varea-Díaz Carlos Corbacho-Fabregat Isabel Bule-Farto Jaime Pérez de-Oteyza |
| |
Institution: | 1. Department of Manufacturing Engineering, ETSII-Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain;2. Department of Corporate Resources, HM Hospitales, Madrid, Spain;3. Department of Hematology, HM Hospitales, Madrid, Spain;4. Department of Anesthesia, HM Hospitales, Madrid, Spain;5. Department of Documentation, HM Hospitales, Madrid, Spain;6. School of Medicine, CEU San Pablo University, Alcorcón, Madrid, Spain |
| |
Abstract: | ObjectiveTo calculate, for the first time, the direct and social costs of transfusion-related adverse events in order to include them in the National Healthcare System's budget, calculation and studies. In Spain more than 1,500 patients yearly are diagnosed with such adverse events.MethodBlood transfusion-related adverse events recorded yearly in Spanish haemovigilance reports were studied retrospectively (2010-2015). The adverse events were coded according to the classification of Diagnosis-Related Groups. The direct healthcare costs were obtained from public information sources. The productivity loss (social cost) associated with adverse events was calculated using the human capital and hedonic salary methodologies.ResultsIn 2015, 1,588 patients had adverse events that resulted in direct health care costs (4,568,914€) and social costs due to hospitalization (200,724€). Three adverse reactions resulted in patient death (at a social cost of 1,364,805€). In total, the cost of blood transfusion-related adverse events was 6,134,443€ in Spain. For the period 2010-2015: the trends show a reduction in the total amount of transfusions (2 vs. 1.91 M€; -4.4%). The number of adverse events increased (822 vs. 1,588; +93%), as well as their related direct healthcare cost (3.22 vs. 4.57M€; +42%) and the social cost of hospitalization (110 vs 200M€; +83%). Mortality costs decreased (2.65 vs. 1.36M€; -48%).DiscussionThis is the first time that the costs of post-transfusion adverse events have been calculated in Spain. These new figures and trends should be taken into consideration in any cost-effectiveness study or trial of new surgical techniques or sanitary policies that influence blood transfusion activities. |
| |
Keywords: | Adverse effects Blood transfusion Health care costs Costs and cost analysis Trends Reacciones adversas Transfusión sanguínea Costes de la atención en salud Costes y análisis de costes Tendencias |
本文献已被 ScienceDirect 等数据库收录! |
|